论文部分内容阅读
目的 :探讨氯氮平治疗帕金森病 (PD)患者中左旋多巴诱导的异动症 (LID)的疗效、合适剂量、不良反应。方法 :对 12例出现LID的PD患者添加氯氮平治疗 ,治疗前后进行UPDRS的异动症评分、运动功能评分和血白细胞的计数。结果 :氯氮平 (5 0± 5 1)mg显著改善了 91 7% (11/12 )PD患者的异动症状 ,治疗前异动症评分为 3 4± 0 7,治疗后为 1 6± 1 3 ,差异显著 (P <0 0 1)。治疗过程中无患者出现运动功能的恶化和血白细胞的减少。结论 :小剂量 (5 0mg)氯氮平能有效改善PD患者的LID ,安全性好
Objective: To investigate the efficacy, appropriate dosage and adverse reactions of clozapine in the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). Methods: Clozapine was given to 12 patients with PD with LID. The ADHD score, motor function score and white blood cell count of UPDRS were measured before and after treatment. Results: Clozapine (5 0 ± 5 1) mg significantly improved the symptoms of 91 7% (11/12) PD patients. The pre-treatment dyskinesia score was 34 ± 0 7 and after treatment was 1 6 ± 1 3 , Significant difference (P <0.01). During the course of treatment, there was no worsening of motor function and a decrease in white blood cells. CONCLUSIONS: Small doses of clozapine (50 mg) can effectively improve the LID in patients with PD, which is safe